Utilization of a nanostructured lipid carrier encapsulating pitavastatin- Pinus densiflora oil for enhancing cytotoxicity against the gingival carcinoma HGF-1 cell line

Drug Deliv. 2023 Dec;30(1):83-96. doi: 10.1080/10717544.2022.2155269.

Abstract

Oral squamous cell carcinoma (OSCC) is the most common epithelial tumor of the oral cavity. Gingival tumors, a unique type of OSCC, account for 10% of these malignant tumors. The antineoplastic properties of statins, including pitavastatin (PV), and the essential oil of the Pinus densiflora leaf (Pd oil) have been adequately reported. The goal of this investigation was to develop nanostructured lipid carriers (NLCs) containing PV combined with Pd oil and to determine their cytotoxicity against the cell line of human gingival fibroblasts (HGF-1). A central composite quadratic design was adopted to optimize the nanocarriers. The particle size and stability index of the nano-formulations were measured to evaluate various characteristics. TEM analysis, the entrapment efficiency, dissolution efficiency, and the cytotoxic efficiency of the optimized PV-loaded nanostructured lipid carrier drug delivery system (PV-Pd-NLCs) were evaluated. Then, the optimal PV-Pd-NLCs was incorporated into a Carbopol 940® gel base and tested for its rheological features and its properties of release and cell viability. The optimized NLCs had a particle size of 98 nm and a stability index of 89%. The gel containing optimum PV-Pd-NLCs had reasonable dissolution efficiency and acceptable rheological behavior and acquired the best cytotoxic activity against HGF-1 cell line among all the formulations developed for the study. The in vitro cell viability studies revealed a synergistic effect between PV and Pd oil in the treatment of gingival cancer. These findings illustrated that the gel containing PV-Pd-NLCs could be beneficial in the local treatment of gingival cancer.

Keywords: Pinus densiflora leaf; Pitavastatin; experimental design; gingival cancer; nanostructured lipid carrier.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Carcinoma, Squamous Cell* / drug therapy
  • Cell Line
  • Drug Carriers / therapeutic use
  • Drug Liberation
  • Excipients
  • Female
  • Gingival Neoplasms* / drug therapy
  • Hepatocyte Growth Factor
  • Humans
  • Lipids
  • Mouth Neoplasms* / drug therapy
  • Nanostructures*
  • Particle Size
  • Pinus*

Substances

  • Drug Carriers
  • Lipids
  • Antineoplastic Agents
  • Excipients
  • HGF protein, human
  • Hepatocyte Growth Factor

Grants and funding

The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number “IFPRC-121-142-2020” and King Abdulaziz University, DSR, Jeddah, Saudi Arabia.